OUS Approvals: Cardiovascular Devices Lead Modest List In July

July 2017 brought 26 approvals from outside the United States, including 14 CE marks in Europe and 12 from five other territories. Almost half of the approvals were for cardiovascular devices; the rest came from eight other categories.

International Flags Blowing In Wind_1200x675
• Source: shutterstock.com

[Editors' note: For sortable and searchable tables of all US and non-US approvals and clearances in 2017 and previous years, check out our Approvals Tracker.]

Medtronic PLC leads July's list of approvals from outside the United States; the firm announced two approvals in Canada,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

Tandem Gears Up For Mobi Tubeless Launch In 2026 After ‘Year Of Transformation’

 
• By 

Tandem Diabetes Care is positioning for growth in 2026 with the launch of its Mobi Tubeless pump following FDA clearance of its Android-compatible Mobi app while navigating multiple recalls during what CEO John Sheridan called a transformative year.

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By 

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By 

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

A Clearer Future For Nearsighted Children? FDA Authorizes Novel Eyeglass Lens To Correct Myopia

 

The US FDA authorization of the Stellest eyeglass lens from French firm EssilorLuxottica could be game-changing for children with myopia, or nearsightedness. The lenses are designed to slow myopia’s progression in children aged 6 to 12.

More from Policy & Regulation

Can Chatbots Treat Depression? FDA Advisers Urge Caution on Generative AI Tools

 
• By 

FDA advisers gave a cautious nod to the idea of using generative AI in mental healthcare during a Nov. 6 panel meeting, saying evidence-backed tools could help expand access – but warning that safety, oversight, and the irreplaceable human connection remain major unanswered questions.

Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls

 

Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.

Global Medtech Guidance Tracker: October 2025

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight’s Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.